(NASDAQ: KYNB) Kyntra Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 24.46%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 67.38%.
Kyntra Bio's earnings in 2026 is $163,615,000.On average, 4 Wall Street analysts forecast KYNB's earnings for 2026 to be -$55,907,665, with the lowest KYNB earnings forecast at -$62,680,966, and the highest KYNB earnings forecast at -$47,945,839. On average, 4 Wall Street analysts forecast KYNB's earnings for 2027 to be -$39,453,304, with the lowest KYNB earnings forecast at -$45,780,908, and the highest KYNB earnings forecast at -$32,176,418.
In 2028, KYNB is forecast to generate -$37,636,512 in earnings, with the lowest earnings forecast at -$44,908,135 and the highest earnings forecast at -$29,371,077.